On Apr 30, 2026, BIO reported earnings of 1.89 USD per share (EPS) for Q1 26, missing the estimate of 2.00 USD, resulting in a -5.68% surprise. Revenue reached 592.10 million, compared to an expected 594.76 million, with a -0.45% difference. The market reacted with a -8.41% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of 1.76 USD, with revenue projected to reach 630.23 million USD, implying an decrease of -6.88% EPS, and increase of 6.44% in Revenue from the last quarter.